Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Kylie O'Keefe"'
Autor:
Lan Gao, Diksha Kaushik, Brian A. Van Tine, Matthew A. Ingham, Steven Attia, Christian F. Meyer, Gary K. Schwartz, Pius Maliakal, John D. Baird, Jiyuan Ma, Rosemary Barrett, Dhiren D'Silva, Kylie O'Keefe, Ronald Kong
Publikováno v:
Clinical and Translational Science, Vol 17, Iss 2, Pp n/a-n/a (2024)
Abstract Unesbulin is being investigated in combination with dacarbazine (DTIC) as a potential therapeutic agent in patients with advanced leiomyosarcoma (LMS). This paper reports the pharmacokinetics (PK) of unesbulin, DTIC, and its unreactive surro
Externí odkaz:
https://doaj.org/article/67669181c17b40ddb322ddfc3dd1c1a1
Autor:
Terri L. Morton, Oscar L. Laskin, Diksha Kaushik, Lucy Lee, Jiyuan Ma, Allan Kristensen, Kylie O'Keefe, Lee Golden, Matthew Klein, Ronald Kong
Publikováno v:
Pharmacology Research & Perspectives, Vol 11, Iss 2, Pp n/a-n/a (2023)
Abstract A therapeutic agent that targets both viral replication and the hyper‐reactive immune response would offer a highly desirable treatment for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2; COVID‐19) management. Emvododsta
Externí odkaz:
https://doaj.org/article/39ad2230eba34f49a3e6b8a52a05b53b
Autor:
Arthur Branstrom, Liangxian Cao, Bansri Furia, Christopher Trotta, Marianne Santaguida, Jason D. Graci, Joseph M. Colacino, Balmiki Ray, Wencheng Li, Josephine Sheedy, Anna Mollin, Shirley Yeh, Ronald Kong, Richard Sheridan, John D. Baird, Kylie O’Keefe, Robert Spiegel, Elizabeth Goodwin, Suzanne Keating, Marla Weetall
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Blocking the pyrimidine nucleotide de novo synthesis pathway by inhibiting dihydroorotate dehydrogenase (DHODH) results in the cell cycle arrest and/or differentiation of rapidly proliferating cells including activated lymphocytes, cancer cells, or v
Externí odkaz:
https://doaj.org/article/811abbf56e4c48f29740cec2bf4b6b7f
Autor:
Terri L. Morton, Oscar L. Laskin, Diksha Kaushik, Lucy Lee, Jiyuan Ma, Allan Kristensen, Kylie O'Keefe, Lee Golden, Matthew Klein, Ronald Kong
Publikováno v:
Pharmacology Research & Perspectives. 11
Autor:
John Babiak, Nicole Risher, Marla Weetall, Diksha Kaushik, Shirley Yeh, Kylie O'Keefe, Valerie Northcutt, Ronald Kong, Young-Choon Moon, Ellen Welch, Lachlan Molony, Jiyuan Ma
Publikováno v:
Xenobiotica. 52:152-164
Emvododstat was identified as a potent inhibitor of dihydroorotate dehydrogenase and is now in clinical development for the treatment of acute myeloid leukaemia and COVID-19. The objective of this paper is to evaluate the metabolism, pharmacokinetics
Autor:
Arthur Branstrom, Liangxian Cao, Bansri Furia, Christopher Trotta, Marianne Santaguida, Jason D. Graci, Joseph M. Colacino, Balmiki Ray, Wencheng Li, Josephine Sheedy, Anna Mollin, Shirley Yeh, Ronald Kong, Richard Sheridan, John D. Baird, Kylie O’Keefe, Robert Spiegel, Elizabeth Goodwin, Suzanne Keating, Marla Weetall
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Blocking the pyrimidine nucleotide de novo synthesis pathway by inhibiting dihydroorotate dehydrogenase (DHODH) results in the cell cycle arrest and/or differentiation of rapidly proliferating cells including activated lymphocytes, cancer cells, or v
Publikováno v:
Journal of Clinical Haematology. 2
Autor:
Brian Andrew Van Tine, Matthew Ingham, Steven Attia, Christian Frederick Meyer, John Baird, Dhiren D'Silva, Kylie O'Keefe, Pius Maliakal, Mona M. Wahba, Marla Weetall, Gary K. Schwartz
Publikováno v:
Journal of Clinical Oncology. 40:11507-11507
11507 Background: Leiomyosarcoma (LMS) is one of the most common subtypes of soft tissue sarcoma and is associated with high risk of relapse and a poor prognosis for advanced disease. In preclinical LMS models, unesbulin, a microtubule polymerization
Autor:
Oscar L. Laskin, Elizabeth Goodwin, Marla Weetall, Diksha Kaushik, Jeffrey R. Infante, Kylie O'Keefe, Joseph M. Colacino, Ronald Kong, Lan Gao, Edward O'Mara, Arthur Branstrom, Robert J. Spiegel, Geoffrey I. Shapiro, Philippe L. Bedard, John D. Baird
Publikováno v:
Clinical pharmacology in drug developmentReferences. 10(8)
PTC596 is a novel, orally bioavailable, small-molecule tubulin-binding agent that reduces B-cell-specific Moloney murine leukemia virus insertion site 1 activity and is being developed for the treatment of solid tumors. A phase 1, open-label, multipl
Autor:
Caterina Strambio-De-Castillia, Stuart W. Peltz, Christopher R. Trotta, Joseph M. Colacino, Elizabeth Goodwin, Liangxian Cao, Yetao Wang, Ellen L Suder, Elke Mühlberger, Sina Bavari, Jason D. Graci, Allan Jacobson, Mark Pykett, Kylie O'Keefe, Rachel A. Sattler, Ronald Kong, Ellen Welch, Jeremy Luban, Katherine Cintron-Lue, Marla Weetall, Slobodan Paessler, Veronica Soloveva, Nikolai Naryshkin
Publikováno v:
Virus Research
bioRxiv
bioRxiv
Highlights • COVID-19 is typified by SARS-CoV-2 replication and excessive inflammatory response. • PTC299 is small orally available DHODH inhibitor that blocks pyrimidine synthesis. • PTC299 is potent inhibitor of the replication of SARS-CoV-2